Speaker: 

Cassandra Lombardo, Pharm.D., PGY1 Pharmacy Resident, Geisinger Medical Center - has nothing to disclose

Mahbuba Choudhury, Pharm.D., PGY Pharmacy Resident, Geisinger Medical Center - has nothing to disclose

Moderator(s): 

Sarah F. Hale, Pharm.D., BCPPS; Director of Pharmacy, Geisinger Medical Center - has nothing to disclose

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Summarize the PROACT Xa trial in determining whether apixaban is noninferior to warfarin in preventing valve thrombosis or valve-related thromboembolism in patients with an On-X mechanical aortic valve
• Propose a place in therapy for apixaban in patients with an On-X mechanical aortic valve.
• Summarize the current treatment options for Staphylococcus aureus.
• Compare differences in new and pipeline treatment options.
• Evaluate Ceftobiprole place in therapy using the the ERADICATE trial

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Sarah F. Hale, PharmD; Brain Simpkins, PharmD; Jessica Milheim, CPhT and Nichole Varela Gonzalez, PharmD have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPPA compliant.